Our range of scientific capabilities spans biologics and small molecules, as well as new drug modalities. We are looking for new and emerging drug platforms that can revolutionise the treatment of diseases. Examples are in vivo expressed biologics, novel bispecific antibodies, and nanobots/smart drug-delivery systems.

We are also harnessing the growing potential of genomic and data science to increase our understanding of disease at the molecular level. This is opening the way to pursuing the next wave of disruptive R&D platforms with new scientific modalities such as PROTACs and cell therapies; new technologies, such as 'omics'; and new biology, such as epigenetics, oligonucleotides and antibody drug conjugates.